Sfoglia per AUTORE
IIDA S
Collezione AOU Città della Salute di Torino
Items : 3
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review. in Frontiers in oncology / Front Oncol. 2025 Mar 12;15:1550644. doi: 10.3389/fonc.2025.1550644. eCollection 2025.
2025
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Gay F; Zamagni E; Cole CE; Scheid C; Hultcrantz M; Chorazy J; Iheanacho I; Pandey A; Bitetti J; Boytsov N; Purser M; McNamara S; Iida S;
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 Dec 1;38(34):4030-4041. doi: 10.1200/JCO.20.02060. Epub 2020 Oct 6.
2020
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Labotka R; Vorog A; Morgan G; Mateos MV; Iida S; Leleu X; Katodritou E; Chng WJ; Beksac M; Bringhen S; Garg M; Hájek R; Oriol A; Quach H; Špi?ka I; Dimopoulos MA; Wang B; Palumbo A; Lonial S;
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
2019
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;